Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706 and Atezolizumab in Extensive Stage Small Cell Lung Cancer
NCT07155174Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Primary completion
- Apr 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 13
01
Overview
A Phase 2 trial of turmetabart adizutecan in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started Nov 2025; status: recruiting.
02
Drugs
turmetabart adizutecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07155174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155174.